Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN). A retrospective survey;Therapie des reizdarmsyndroms mit Escherichia coli stamm Nissle 1917 (EcN). Eine retrospektive untersuchung

Medizinische Klinik

Volumn 102, Issue 11, 2007, Pages 888-892

  Plaßmann, Dominik ^b   Schulte Witte, Hildegard ^a  

^a Praxis für Innere Medizin Gastroenterologie   (Germany)

^b NONE   (Germany)

Author keywords

Constipation; Diarrhea; E. coli Nissle 1917; Irritable bowel syndrome (IBS); Meteorism

Indexed keywords

MUTAFLOR; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FECES ANALYSIS; FLATULENCE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; METEORISM; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ESCHERICHIA COLI; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROBIOTICS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

ESCHERICHIA COLI NISSLE 1917;

EID: 36249014930     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-007-1116-2     Document Type: Article

References (26)

1. Andresen V, Baumgart DC. Role of probiotics in the treatment of irritable bowel syndrome: potential mechanisms and current clinical evidence. Int J Probiotics Prebiotics 2006;1:11-8.
2. Bischoff SC, Manns MP. Probiotika, Präbiotika und Synbiotika. Stellenwert in Klinik und Praxis. Dtsch Ärztebl 2005;102:B630-7.
3. Böhm SK, Kruis, W. Diagnostik und Therapie des Reizdarmsyndroms. Gastroenterologie up2date 2006;2:271-306.
4. Bruckschen E, Horosiewicz H. Chronische Obstipation. Vergleich von mikrobiologischer Therapie und Lactulose. Münch Med Wochenschr 1994; 136: 241-5.
5. Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 2001;120:652-68.
6. Drossman DA, Richter JE, Talley NJ, et al., eds. The functional gastrointestinal disorders: diagnosis, pathophysiology and treatment. McLean: Degnon Associates, 1994.
7. Hamilton-Miller JMT. Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microbial Ecol Health Dis 2001;13:212-6.
8. Henker J, Blokhin B, Bolbot J, et al. The probiotic E. coli Nissle 1917 stops acute diarrhoea in infants and toddlers. Eur J Pediatr 2007;166:311-8.
9. Krammer HJ, Kämper H, Bünau R von, et al. Probiotische Arzneimitteltherapie mit E. coli Stamm Nissle 1917 (EcN): Ergebnisse einer prospektiven Datenerhebung mit 3807 Patienten. Z Gastroenterol 2006;44:651-6.
10. Krammer HJ, Schlieger F, Harder H, et al. Probiotics as therapeutic agents in irritable bowel syndrome. Z Gastroenterol 2005;43:467-71.
11. Kruis W, Chrubasik S, Stange C, et al. Therapeutic efficacy of the probiotic E. coli Nissle 1917 in subgroups of irritable bowel syndrome. Gut 2004;53:Suppl 6:A208-9.
12. Kruis W, Frič P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-23.
13. Kruis W, Thieme C, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984;87:1-7.
14. Lembo A. Irritable bowel syndrome medications side effects survey. J Clin Gastroenterol 2004;38:776-81.
15. Longstreth GF, Thompson WG, Chey W, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91.
16. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2:653-4.
17. Möllenbrink M, Bruckschen E. Behandlung der chronischen Obstipation mit physiologischen Escherichia-coli-Bakterien. Med Klin 1994;89:587-93.
18. Montrose DC, Floch MH. Probiotics used in human studies. J Clin Gastroenterol 2005;39:469-84.
19. Nobaek S, Johansson ML, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-8.
20. Pfannkuche HJ, Dennis E. Tegaserod-induced myocardial infarction: case report and hypothesis - an alternative viewpoint. Pharmacotherapy 2004;24:1649-50.
21. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 1990;99:409-15.
22. Schütz E. Behandlung von Darmerkrankungen mit MUTAFLOR. Eine multizentrische retrospektive Erhebung. Fortschr Med 1989;107:599-602.
23. Sullivan A, Nord CE. Probiotics and gastrointestinal diseases. J Intern Med 2005;257:78-92.
24. Thompson WG, Creed F, Drossman DA, et al. Functional bowel disease and functional abdominal pain. Gastroenterol Int 1992;5:75-91.
25. Thompson WG, Dotevall G, Drossman DA, et al. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int 1989;2:92-5.
26. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999;45:Suppl 2:43-7.